<DOC>
	<DOCNO>NCT01850147</DOCNO>
	<brief_summary>The purpose study determine whether sequential application low-dose short-term sunitinib chemotherapy effective treatment non-small cell lung cancer failure conventional therapy . Safety regimen also evaluate .</brief_summary>
	<brief_title>Sequential Use Low-dose Sunitinib With Chemotherapy Advanced NSCLC After Failure Conventional Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologic cytologic diagnosis stage IIIB/IV NSCLC ECOG PS : 0,1 Unidimensional bidimensional measurable disease Receive prior treatment include firstline platinumbased chemotherapy , standard secondline chemotherapy 1 EGF/EGFR inhibitor Evidence disease progression Life expectancy &gt; 12 week Neutrophils &gt; 1.5 109/l , Platelets &gt; 100 109/l , Hemoglobin &gt; 9g/dl , Total bilirubin &lt; 1.5 UNL , AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 UNL , Alkaline phosphatases &lt; 5 UNL , Creatinine &lt; 1 UNL Preexisting hemoptysis severity &gt; grade 3 NCI CTCAE criterion within 4 week prior study entry Uncontrolled hypertension CHF , angina arrhythmia LVEF &lt; 1 UNL Existing second malignancy within 5 year Infected HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>